Favorable vascular profile is an independent predictor of outcome: A post hoc analysis of the safety and efficacy of NeuroFlo technology in ischemic stroke trial

Stroke

Volumn 44, Issue 6, 2013, Pages 1606-1608

  Schellinger, Peter D ^a   Köhrmann, Martin ^b   Liu, Songling ^c   Dillon, William P ^c   Nogueira, Raul G ^d   Shuaib, Ashfaq ^e   Liebeskind, David S ^f  

^a KLINIKUM MINDEN   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aortic occlusion; Brain perfusion augmentation; Clinical trials; Ischemic stroke; SENTIS

Indexed keywords

ARTICLE; BRAIN CIRCULUS ARTERIOSUS; BRAIN ISCHEMIA; BRAIN PERFUSION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; FAVORABLE VASCULAR PROFILE; HEMODYNAMICS; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MEDICAL DEVICE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROANATOMY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE;

AORTIC OCCLUSION; BRAIN PERFUSION AUGMENTATION; CLINICAL TRIALS; ISCHEMIC STROKE; SENTIS;

ANGIOGRAPHY; AORTA, ABDOMINAL; BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; CIRCLE OF WILLIS; EQUIPMENT AND SUPPLIES; EQUIPMENT SAFETY; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGIONAL BLOOD FLOW; STROKE; THERAPEUTIC OCCLUSION; TREATMENT OUTCOME;

EID: 84880180350     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000709     Document Type: Article

References (9)

1. Shuaib A, Bornstein NM, Diener HC, Dillon W, Fisher M, Hammer MD, et al.; SENTIS Trial Investigators. Partial aortic occlusion for cerebral perfusion augmentation: safety and effcacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke. 2011;42:1680-1690.
2. Hammer M, Jovin T, Wahr JA, Heiss WD. Partial occlusion of the descending aorta increases cerebral blood fow in a nonstroke porcine model. Cerebrovasc Dis. 2009;28:406-410.
3. Emery DJ, Schellinger PD, Selchen D, Douen AG, Chan R, Shuaib A, et al. Safety and feasibility of collateral blood fow augmentation after intravenous thrombolysis. Stroke. 2011;42:1135-1137.
4. Liebeskind DS. Aortic occlusion for cerebral ischemia: from theory to practice. Curr Cardiol Rep. 2008;10:31-36.
5. Liebeskind DS. Reperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics. Curr Opin Neurol. 2010;23:36-45.
6. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al.; EPITHET Investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
7. Thomalla GJ, Kucinski T, Schoder V, Fiehler J, Knab R, Zeumer H, et al. Prediction of malignant middle cerebral artery infarction by early perfusion-and diffusion-weighted magnetic resonance imaging. Stroke. 2003;34:1892-1899.
8. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al.; DEFUSE Investigators. Magnetic resonance imaging profles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
9. Mlynash M, Lansberg MG, De Silva DA, Lee J, Christensen S, Straka M, et al.; DEFUSE-EPITHET Investigators. Refning the defnition of the malignant profle: insights from the DEFUSE-EPITHET pooled data set. Stroke. 2011;42:1270-1275.